Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm About Xinnate receives Orphan Drug Designation from US FDA for TCP-25 New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD Team Xinnate announces successful FDA meeting for TCP-25 Opportunity Scientific Foundation Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa Modes of action Approved clinical trial application for BioC gel on complex wounds Xinnate presents TCP-25 data at international dermatology congress Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa Upcoming events Excellent results from phase I study shows that the BioC gel is safe and well tolerated. Publications Contact News The Unique Concept Funding secured for the next step of BioC clinical plan Xinnate raises SEK 31 million in oversubscribed share issue Xinnate completes Phase 1a/b study with TCP-25 Approved clinical trial application for First in Human study on BioC gel The Need Home 2 The Market Test news item IPR Idea Concept Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa Xinnate appoints Anna-Karin Lindqvist as new COO Test News 2 Pre-clinical results Test News 3 Xinnate is awarded a prestigious grant from the US Department of Defense The Competition New publication: BioC-coated dressing shows promising effect on both infection and inflammation Funding secured for the first clinical study of BioC wound gel Xinnate has received a prestigious Swedish Research Council grant Great interest for the STM article and coverage in Nature Reviews Drug Discovery Strategy Breakthrough results published in Science Translational Medicine Xinnate is looking for a Chief Operating Officer Integritetspolicy A new article about BioC results from Lund University Knowledge Platform Exempelsida Home4